Celcuity Inc (CELC) Stock Price, Quote & News

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology

Sector: Healthcare

Phone: 763 392 0767

Website: www.celcuity.com

Address:

16305 36th Avenue North, Suite 100, Minneapolis, United States

twincam Apr. 3 at 12:27 AM

$BMY $CELC BMS staring down a massive patent cliff on Eliquis & Opdivo (~$20B+ at risk by 2028). CEO casting a broad net for bolt-ons in oncology & in vivo autoimmune platforms. Fits: $CELC (Phase 3 gedatolisib breast cancer data imminent — Wolfe calls it top-tier takeover target) or next in vivo CAR-T plays like their $1.5B Orbital deal. Who’s next on BMY’s shopping list?

0 · Reply

moneybag888 Apr. 1 at 1:17 AM

$MRVL $CELC

0 · Reply

moneybag888 Apr. 1 at 1:14 AM

$CELC

1 · Reply

NedFlandersIII Mar. 30 at 6:07 PM

$CELC this stock has kept me afloat all year. Ty celc. Like the kids say: "you're him forreal" 🤝💸

0 · Reply

West_Bale Mar. 28 at 3:09 AM

$CELC There is a high chance gedatolisib with an ET and a CDK 4/6i becomes the foundational therapy for HR+, HER2- ABC. This type of ABC represents 70% of ABC. The results have been so far very promising. It can further extend PFS for patients who were previously on CDK4/6i.

0 · Reply

StockConsultant Mar. 27 at 1:06 PM

$CELC Celcuity stock watch, a few strong days up to resistance, watch for a top of range breakout at https://stockconsultant.com/?CELC

0 · Reply

CharlieeMungerTWITS Mar. 27 at 11:12 AM

$CELC $ARVN running the math on float, each one has about 9-12m shares available for retail. The rest are locked up. Both are well funded. Pdufa inbound. @Steve_TheBull_Rogers

0 · Reply

CharlieeMungerTWITS Mar. 26 at 11:50 PM

$CELC

0 · Reply

moneybag888 Mar. 26 at 7:25 PM

$CELC $MDGL $LLY

1 · Reply

spinusn27 Mar. 26 at 5:26 PM

$CELC @kod another baker brothers stoc- need to check this one out.

0 · Reply

Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript

Mar 25, 2026, 4:01 PM EDT - 10 days ago

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 18, 2026, 8:00 AM EDT - 17 days ago

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call

Mar 10, 2026, 4:20 PM EDT - 25 days ago

Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 9, 2026, 5:42 PM EDT - 26 days ago

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology

Mar 9, 2026, 2:28 PM EDT - 26 days ago

Celcuity Inc. (CELC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 1:38 PM EST - 4 weeks ago

Artisan International Small-Mid Fund Q4 2025 Performance Review

LEGN LIVN NICE

Feb 25, 2026, 4:01 PM EST - 5 weeks ago

Celcuity To Participate in Upcoming Investor Conferences

Feb 13, 2026, 4:17 PM EST - 7 weeks ago

Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 12, 2026, 4:05 PM EST - 7 weeks ago

Celcuity Appoints Charles Romp to its Board of Directors

Feb 4, 2026, 7:05 AM EST - 2 months ago

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 22, 2026, 10:26 AM EST - 2 months ago

These 20 stocks are strong choices for momentum investors

BE COGT FBYD FRGE INBX KOD LITE

Jan 20, 2026, 7:30 AM EST - 2 months ago

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Dec 24, 2025, 11:25 AM EST - 3 months ago

Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond

Dec 11, 2025, 2:35 PM EST - 4 months ago

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 28, 2025, 7:30 AM EST - 4 months ago

Celcuity: From Speculative Bet To Pre-Commercial Powerhouse

Nov 26, 2025, 4:05 PM EST - 4 months ago

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Nov 26, 2025, 7:05 AM EST - 4 months ago

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

Nov 17, 2025, 4:05 PM EST - 4 months ago

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

Nov 12, 2025, 8:01 PM EST - 5 months ago

Celcuity Inc. (CELC) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:01 PM EST - 5 months ago

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:05 AM EST - 5 months ago

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Nov 4, 2025, 7:05 AM EST - 5 months ago

Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference

Oct 21, 2025, 5:41 PM EDT - 5 months ago

Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results

Oct 20, 2025, 5:05 PM EDT - 5 months ago

Celcuity Inc. (CELC) Discusses Additional Results From Phase III VIKTORIA-1 Trial and Insights Into PAM Pathway Targeting Transcript

Oct 20, 2025, 9:42 AM EDT - 5 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CRMD RANI RAPT

Oct 18, 2025, 4:30 AM EDT - 6 months ago

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Oct 18, 2025, 4:30 AM EDT - 6 months ago

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Oct 18, 2025, 4:30 AM EDT - 6 months ago

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

Oct 8, 2025, 11:22 AM EDT - 6 months ago

Celcuity: Blink And You Missed It

Sep 22, 2025, 9:15 AM EDT - 6 months ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Sep 9, 2025, 4:01 PM EDT - 7 months ago

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance

Aug 27, 2025, 4:05 PM EDT - 7 months ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program

Aug 15, 2025, 11:40 AM EDT - 8 months ago

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:01 PM EDT - 8 months ago

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:05 AM EDT - 8 months ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Jul 30, 2025, 3:42 PM EDT - 8 months ago

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Jul 30, 2025, 6:30 AM EDT - 8 months ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

Jul 29, 2025, 6:40 AM EDT - 8 months ago

Celcuity: What's Happening With CELC Stock?

Jul 28, 2025, 4:02 PM EDT - 8 months ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

Jul 28, 2025, 3:02 PM EDT - 8 months ago

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Jul 28, 2025, 7:49 AM EDT - 8 months ago

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Jul 28, 2025, 7:00 AM EDT - 8 months ago

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Jul 25, 2025, 4:05 PM EDT - 9 months ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Jul 24, 2025, 4:01 PM EDT - 9 months ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Jul 14, 2025, 7:05 AM EDT - 9 months ago

Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042

Jun 30, 2025, 7:05 AM EDT - 9 months ago

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

May 21, 2025, 7:05 AM EDT - 11 months ago

Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

May 14, 2025, 9:36 PM EDT - 11 months ago

Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 11 months ago

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

twincam Apr. 3 at 12:27 AM

0 · Reply

moneybag888 Apr. 1 at 1:17 AM

$MRVL $CELC

0 · Reply

moneybag888 Apr. 1 at 1:14 AM

$CELC

1 · Reply

NedFlandersIII Mar. 30 at 6:07 PM

$CELC this stock has kept me afloat all year. Ty celc. Like the kids say: "you're him forreal" 🤝💸

0 · Reply

West_Bale Mar. 28 at 3:09 AM

0 · Reply

StockConsultant Mar. 27 at 1:06 PM

$CELC Celcuity stock watch, a few strong days up to resistance, watch for a top of range breakout at https://stockconsultant.com/?CELC

0 · Reply

CharlieeMungerTWITS Mar. 27 at 11:12 AM

$CELC $ARVN running the math on float, each one has about 9-12m shares available for retail. The rest are locked up. Both are well funded. Pdufa inbound. @Steve_TheBull_Rogers

0 · Reply

CharlieeMungerTWITS Mar. 26 at 11:50 PM

$CELC

0 · Reply

moneybag888 Mar. 26 at 7:25 PM

$CELC $MDGL $LLY

1 · Reply

spinusn27 Mar. 26 at 5:26 PM

$CELC @kod another baker brothers stoc- need to check this one out.

0 · Reply

SannieVerraderlijk Mar. 26 at 4:08 PM

$KZIA Opened position in KZIA = $CELC me-too

0 · Reply

erevnon Mar. 26 at 3:23 PM

Stifel maintains Celcuity $CELC at Buy and raises the price target from $115 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

moneybag888 Mar. 26 at 2:48 PM

$CELC

0 · Reply

CharlieeMungerTWITS Mar. 26 at 2:11 PM

$RCKT <~~~~~ all aboard for pdufa tomorrow ! $GRCE $CELC

1 · Reply

CharlieeMungerTWITS Mar. 26 at 2:08 PM

$ARVN $CELC that’s a good little boy. You keep going up 8% a day

0 · Reply

SuperGreenToday Mar. 26 at 12:10 PM

$CELC Share Price: $110.53 Contract Selected: Sep 18, 2026 $110 Calls Buy Zone: $24.07 – $29.73 Target Zone: $44.97 – $54.96 Potential Upside: 76% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Mar. 26 at 11:32 AM

Stifel⬆️ $CELC's PT to $125 from $115 and reiterated a Buy rating. $RLAY $RHHBY LLY BBOT NVS BGNE Here's what Stifel said in its note: https://x.com/Quantumup1/status/2037129947924336805?s=20

0 · Reply

CharlieeMungerTWITS Mar. 26 at 12:13 AM

$ARVN $CELC I expect you two gems to perk up hard very soon

0 · Reply

moneybag888 Mar. 25 at 9:00 PM

$CELC when buyout? 150 or 200

2 · Reply

TheFro123 Mar. 25 at 8:58 PM

$CELC great update!!!

1 · Reply

CharlieeMungerTWITS Mar. 25 at 11:36 AM

$ARVN $CELC these two will be yuuuuuuuge

0 · Reply

HappyStockholder Mar. 24 at 8:24 PM

$CELC WOW!!! Another big buy from the Baker Bros.

0 · Reply

Market Cap	5.44B
Revenue (ttm)	0.00
Net Income (ttm)	-177.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.26

Volume	501,300
Avg Vol	742,714
Day's Range	N/A - N/A
Shares Out	48.34M
Stochastic %K	67%
Beta	0.41
Analysts	Strong Sell
Price Target	$128.60